跳至主要内容
临床试验/NCT02039232
NCT02039232已完成不适用

CarboFix Pedicle Screw System

CarboFix Orthopedics Ltd.3 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2014年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
46
试验地点
3
主要终点
Fusion success

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy of CarboFix' Pedicle Screw System in the lumbar spine.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is 18 years old or older.
  • Confirmation that the physical examination of radiopathy, myelopathy or combination is in correlation with the affected level.
  • Lumbar CT, MRI, or myelography confirms the level of involvement is consistent with the subject's examination.
  • Informed consent given by the subject.

排除标准

  • Subject is not eligible for fixation with market-available fixation means.
  • Familial history NF
  • Acute traumatic spinal injury with or without neurological signs.
  • Metabolic bone disease.
  • History of Paget's disease or other osteodystrophies whether acquired or congenital, including renal osteodystrophy, hyperthyroidism, hypothyroidism hyperparathyroidism, Ehrlers-Danlos-syndrome, osteogenesis imperfecta, achondroplasia, tuberculosis.
  • History of mental disorder or current psychiatric treatment.
  • Pregnancy and/or female subjects intending to become pregnant within the expected time frame of the study and/or female subjects of child bearing age who do not use conventional contraceptive methods.
  • Immune deficiency disease.
  • Infection in the location of the operative site, discitis, osteomyelitis, fever and/or leukocytosis (as diagnosed based on the results of CBC and ESR tests).
  • Treatment with drugs that may interfere with bone metabolism such as:
  • Cumulative dose of 150 mg. of Prednisone or equivalent within the last 6 months.
  • Calcitonin within the past 6 months.
  • Bisphosphonates for 30 days or more within the last 12 months.
  • Bone therapeutic doses of fluoride for 30 days or more within the last 12 months.
  • Bone therapeutic doses of vitamin D or Vitamin D metabolites for 30 days or more within the last 6 months.
  • Treatment by chemotherapy within the last 12 months.
  • Lack of willingness to make a commitment to return for required follow up visits.
  • Drug and/or alcohol abuse.
  • Morbid obesity.
  • Metal allergies.
  • Recent use of other investigational drugs or devices (within the past 30 days).

结局指标

主要结局

Fusion success

时间窗: 6 months post-operation

次要结局

未报告次要终点

研究者

发起方
CarboFix Orthopedics Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验